Nanoparticles as carriers for drug delivery in cancer
Source abstract
Abstract
Cancer nanotherapeutics are swiftly progressing and are being applied to solve several limitations of conventional drug delivery systems such as non-specific biodistribution and targeting, lack of water solubility and poor oral bioavailability. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. Nanoparticles have been designed for optimal size and surface characteristics to improve their biodistribution and to increase their circulation time in the bloodstream. By selectively using the unique pathophysiology of tumours, such as their enhanced permeability and retention effect nanotherapeutics are able to carry loaded active drug to cancer cells. In addition to this passive targeting mechanism, active targeting strategies using ligands or antibodies directed against selected tumour targets magnify the specificity of these therapeutic nanoparticles. Drug resistance, another obstacle can also be overcome or reduced by using nanoparticles. Multifunctional and multiplex nanoparticles are now being actively investigated and are on the horizon as the next generation of nanoparticles, facilitating personalized and tailored cancer treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, I.S.F. College of Pharmacy, Moga, India;
Department of Pharmaceutical Science and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, India
References (64)
Show source-provided references
1. Stewart BW · 2003
2. Society AC. · 2007
3. 10.1309/5CWPU41AFR1VYM3F10.1309/5CWPU41AFR1VYM3F ↗
4. 10.1158/1078-0432.CCR-07-144110.1158/1078-0432.CCR-07-1441 ↗
5. 10.1016/S0065-2571(00)00013-310.1016/S0065-2571(00)00013-3 ↗
6. 10.1038/nrc90310.1038/nrc903 ↗
7. 10.1038/nrc195810.1038/nrc1958 ↗
8. 10.1038/nrc156610.1038/nrc1566 ↗
9. Moghimi SM · Pharmacol Rev · 2001 · 53 · 28310.1016/S0031-6997(24)01494-7 ↗
10. 10.1016/S0163-7827(03)00033-X10.1016/S0163-7827(03)00033-X ↗
11. 10.2165/00003088-200140070-0000510.2165/00003088-200140070-00005 ↗
12. 10.1177/01926233960240011410.1177/019262339602400114 ↗
13. Yuan F · Cancer Res · 1995 · 55 · 3752
14. 10.1007/s11095-006-0284-810.1007/s11095-006-0284-8 ↗
15. 10.1016/j.biopha.2004.01.00710.1016/j.biopha.2004.01.007 ↗
16. Matsumura Y · Cancer Res · 1986 · 46 · 6387
17. 10.1038/nrd163210.1038/nrd1632 ↗
18. 10.1073/pnas.95.8.460710.1073/pnas.95.8.4607 ↗
19. 10.1038/nrc70610.1038/nrc706 ↗
20. 10.1016/j.canlet.2005.06.00310.1016/j.canlet.2005.06.003 ↗
21. 10.1038/scientificamerican0794-5810.1038/scientificamerican0794-58 ↗
22. de Menezes DEL · Cancer Res · 1998 · 58 · 3320
23. Park JW · Clin Cancer Res · 2002 · 8 · 1172
24. 10.1038/nrc189110.1038/nrc1891 ↗
25. 10.1073/pnas.060849110410.1073/pnas.0608491104 ↗
26. Sapra P · Cancer Res · 2002 · 62 · 7190
27. 10.1016/0165-6147(94)90314-X10.1016/0165-6147(94)90314-X ↗
28. 10.1016/j.chembiol.2006.11.01510.1016/j.chembiol.2006.11.015 ↗
29. 10.1200/JCO.2005.04.93710.1200/JCO.2005.04.937 ↗
30. 10.1200/JCO.2004.12.04310.1200/JCO.2004.12.043 ↗
31. 10.1021/jm020022r10.1021/jm020022r ↗
32. Vasey PA · Clin Cancer Res · 1999 · 5 · 83
33. 10.1517/14656566.7.11.146910.1517/14656566.7.11.1469 ↗
34. 10.3816/CBC.2003.s.01910.3816/CBC.2003.s.019 ↗
35. 10.1097/00000421-200202000-0001210.1097/00000421-200202000-00012 ↗
36. 10.1038/bjc.1996.58710.1038/bjc.1996.587 ↗
37. 10.1016/S0168-3659(01)00341-810.1016/S0168-3659(01)00341-8 ↗
38. 10.1158/1078-0432.CCR-03-065510.1158/1078-0432.CCR-03-0655 ↗
39. 10.1097/00001813-199909000-0001010.1097/00001813-199909000-00010 ↗
40. 10.1248/bpb.29.179010.1248/bpb.29.1790 ↗
41. 10.1093/annonc/mdl10410.1093/annonc/mdl104 ↗
42. 10.1200/JCO.2004.00.614810.1200/JCO.2004.00.6148 ↗
43. 10.1016/S0169-409X(02)00045-510.1016/S0169-409X(02)00045-5 ↗
44. 10.1038/nrd108810.1038/nrd1088 ↗
45. 10.1002/jps.1039710.1002/jps.10397 ↗
46. 10.1021/nl061412u10.1021/nl061412u ↗
47. 10.1016/0009-3084(93)90071-A10.1016/0009-3084(93)90071-A ↗
48. 10.1097/01.cad.0000167902.53039.5a10.1097/01.cad.0000167902.53039.5a ↗
49. 10.1016/j.ijpharm.2006.02.02710.1016/j.ijpharm.2006.02.027 ↗
50. 10.1016/j.addr.2006.09.01410.1016/j.addr.2006.09.014 ↗
51. 10.1186/1477-3155-4-210.1186/1477-3155-4-2 ↗
52. 10.1002/smll.20100052310.1002/smll.201000523 ↗
53. 10.1007/s12013-014-0363-010.1007/s12013-014-0363-0 ↗
54. 10.1016/j.biomaterials.2011.05.04710.1016/j.biomaterials.2011.05.047 ↗
55. 10.1002/chem.20120003010.1002/chem.201200030 ↗
56. 10.1016/j.biomaterials.2010.09.06510.1016/j.biomaterials.2010.09.065 ↗
57. 10.1002/adfm.20100145010.1002/adfm.201001450 ↗
58. 10.1021/nl202949y10.1021/nl202949y ↗
59. 10.1021/nn103419710.1021/nn1034197 ↗
60. 10.1158/0008-5472.CAN-12-100310.1158/0008-5472.CAN-12-1003 ↗
61. 10.1200/JCO.2005.10.01710.1200/JCO.2005.10.017 ↗
62. 10.1056/NEJMoa01179510.1056/NEJMoa011795 ↗
63. 10.1056/NEJM20010405344140110.1056/NEJM200104053441401 ↗
64. 10.1517/14712598.8.8.106310.1517/14712598.8.8.1063 ↗